Back to search

Article

Sorafenib Combined with DOAP Regimen for the Treatment of BRAF V600E-Negative Langerhans Cell Sarcoma: A three-year follow-up result

2024-09-02

Abstract excerpt

<h4>Objective: </h4> The purpose of this study is to investigate the clinical efficacy of the combination therapy of sorafenib and DOAP (doxorubicin, vincristine, cytarabine, and prednisone) in the treatment of a case of Langerhans cell sarcoma (LCS) negative for BRAF V600E mutation. Furthermore, we aim to retrospectively analyze the clinical characteristics, diagnosis, treatment, and prognosis of LCS. <h4>Method...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
b7f1f2b5-ba34-5ebf-bb26-6bf755b2e678
DOI
10.22541/au.172528798.87557705/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Sorafenib Combined with DOAP Regimen for the Treatment of BRAF V600E-Negative Langerhans Cell Sarcoma: A three-year follow-up resultDOI 10.22541/au.172528798.87557705/v1
Select a neighboring publication to make it the new centre.